Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Blood (2012) 120 (21): 2590.

https://doi.org/10.1182/blood.V120.21.2590.2590

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Naveen Pemmaraju, M.D., Hagop M. Kantarjian, MD, Kathy M. Tran, Syed M. Kazmi, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Zeev Estrov, MD, PhD, Stefan Faderl, MD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD

Blood (2012) 120 (21): 2592.

https://doi.org/10.1182/blood.V120.21.2592.2592

Published: 2012

Journal Articles

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Guillermo Garcia-Manero, MD, Susan O'Brien, M.D., Stefan Faderl, MD, Rajyalakshmi Luthra, Ph.D., William G. Wierda, MD, Ph.D., Alessandra Ferrajoli, Sherry A. Pierce, RN, BS, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2562.

https://doi.org/10.1182/blood.V120.21.2562.2562

Published: 2012

Journal Articles

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Farhad Ravandi, MD, Keyur P. Patel, MD, PhD, Rajyalakshmi Luthra, Ph.D., Sherry A. Pierce, RN, BS, Gautam Borthakur, M.D., Elias J. Jabbour, MD, Tapan M. Kadia, M.D., Naveen Pemmaraju, M.D., Naval Daver, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Jorge E Cortes, MD, Hagop M. Kantarjian, MD

Blood (2012) 120 (21): 2483.

https://doi.org/10.1182/blood.V120.21.2483.2483

Published: 2012

Journal Articles

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Keyur P. Patel, MD, PhD, Guillermo Garcia Manero, Ohad Benjamini, MD, Gautam Borthakur, M.D., Naveen Pemmaraju, M.D., Tapan M. Kadia, M.D., Naval G. Daver, MD, Aziz Nazha, Rajyalakshmi Luthra, PhD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2484.

https://doi.org/10.1182/blood.V120.21.2484.2484

Published: 2012

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Elias J. Jabbour, MD, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Alfonso Quintás-Cardama, MD, Rajyalakshmi Luthra, PhD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2623.

https://doi.org/10.1182/blood.V120.21.2623.2623

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.

Syed M. Kazmi, MD, Hagop M. Kantarjian, MD, Kathy M. Tran, Jorge E. Cortes, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Elias J. Jabbour, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Naval Daver, MD, Sherry A. Pierce, RN, BS, Aziz Nazha, Alfonso Quintas-Cardama, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 2587.

https://doi.org/10.1182/blood.V120.21.2587.2587

Published: 2012

Journal Articles

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Hady Ghanem, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Sherry A. Pierce, RN, BS, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 2627.

https://doi.org/10.1182/blood.V120.21.2627.2627

Published: 2012

Journal Articles

A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, MD, Wei Qiao, Sherry A. Pierce, RN, BS, Mimmo Ripaldi, MD, Stefan Faderl, MD, Hagop M Kantarjian, William G. Wierda, MD, PhD, Jorge E Cortes, MD

Blood (2012) 120 (21): 131.

https://doi.org/10.1182/blood.V120.21.131.131

Published: 2012

Journal Articles

Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs).

Naveen Pemmaraju, M.D., Hagop M Kantarjian, M.D., Jorge E. Cortes, MD, Alfonso Quintas-Cardama, MD, Sherry A. Pierce, RN, BS, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 2845.

https://doi.org/10.1182/blood.V120.21.2845.2845

Published: 2012

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 1693.

https://doi.org/10.1182/blood.V120.21.1693.1693

Published: 2012

Journal Articles

Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS)

Yue Wei, PhD, Rui Chen, Sophie Dimicoli, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Donna S. Neuberg, ScD, Sherry A. Pierce, RN, BS, Hui Yang, MD, PhD., Yu Jia, Hong Zheng, Zhihong Fang, Martin Nguyen, Michael Fernandez, Sa A. Wang, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 1700.

https://doi.org/10.1182/blood.V120.21.1700.1700

Published: 2012

Journal Articles

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Mona Lisa Alattar, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Maro Ohanian, DO, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Alfonso Quintas-Cardamas, MD, Elias Jabbour, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Stefan Faderl, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 1456.

https://doi.org/10.1182/blood.V120.21.1456.1456

Published: 2012

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Megan Othus, PhD, Hagop M. Kantarjian, MD, Stephen Petersdorf, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Sherry A. Pierce, RN, BS, Harry Paul Erba, MD, PhD, Stefan Faderl, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 129.

https://doi.org/10.1182/blood.V120.21.129.129

Published: 2012

Journal Articles

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Christopher B. Benton, MD, Peng Qiu, PhD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, RN, BS, Anisha Borthakur, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Michael Andreeff, MD, PhD, Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1417.

https://doi.org/10.1182/blood.V120.21.1417.1417

Published: 2012

Journal Articles

Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, MD, Ohad Benjamini, MD, Sherry A. Pierce, RN, BS, Marylou Cardenas-Turanzas, Srdan Verstovsek, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 70.

https://doi.org/10.1182/blood.V120.21.70.70

Published: 2012

Journal Articles

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju, M.D., Deborah Thomas, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, John T Manning, MD, L. Jeffrey Medeiros, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Aziz Nazha, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Stefan Faderl, MD

Blood (2012) 120 (21): 3554.

https://doi.org/10.1182/blood.V120.21.3554.3554

Published: 2012

Journal Articles

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Cecilia Y Arana Yi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD, Ph.D., Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Michael Andreeff, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3557.

https://doi.org/10.1182/blood.V120.21.3557.3557

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).

Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.

Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC

Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs).

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS)

Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only